Siglec–15 promotes a feed-forward loop between TNBC cells and macrophages via the NF- κB/DcR3/CCL18/STAT3 axis
This study reveals that Siglec-15 drives a feed-forward loop in triple-negative breast cancer by activating the NF-κB/DcR3 pathway to induce M2-like macrophage polarization and CCL18 secretion, which in turn enhances Siglec-15 expression via STAT3 phosphorylation to further promote tumor progression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is a complex disease, but one of its most aggressive forms, known as triple-negative breast cancer, presents a particularly difficult challenge for doctors. Unlike other types, this form lacks specific receptors that usually allow for targeted treatments, leaving patients with fewer options and a higher risk of the disease returning. To understand why this cancer is so dangerous, scientists look beyond the tumor cells themselves to the environment surrounding them. This environment, often called the tumor microenvironment, is a bustling neighborhood filled with various types of cells, including immune cells known as macrophages. Normally, these immune cells act as the body's security guards, hunting down invaders. However, in the presence of a tumor, these guards can be tricked into switching sides, becoming helpers that feed the cancer's growth and help it spread. One specific protein found on the surface of some cancer cells, called Siglec-15, has recently been identified as a key player in this deception, but exactly how it manipulates the immune system to aid the tumor has remained a mystery.
A team of researchers at Qingdao University has now mapped out the secret communication lines between these cancer cells and the immune cells they recruit. By studying tissue samples from patients and running a series of experiments in the lab, they discovered that triple-negative breast cancer cells with high levels of Siglec-15 do not just sit passively; they actively send out signals that reprogram nearby immune cells. Specifically, the cancer cells use Siglec-15 to turn neutral immune cells into a harmful type that supports the tumor. This process is not a one-way street. Once these immune cells are converted, they release their own chemical signals that travel back to the cancer cells, telling them to produce even more of the Siglec-15 protein. This creates a self-reinforcing cycle, a loop where the cancer and its immune helpers constantly boost each other's strength, making the tumor more aggressive and harder to stop.
To uncover this mechanism, the researchers began by examining a vast collection of genetic data from thousands of patients. They used advanced computer tools to sort through millions of individual cells, looking for patterns that distinguished the most dangerous tumor cells from the rest. They identified a specific group of cancer cells that were linked to poor survival rates. When they looked closely at what these cells were doing, they found they were heavily interacting with immune cells in the tumor's neighborhood. The researchers then turned to the lab to see this interaction in action. They grew human cancer cells in dishes and mixed them with immune cells. When the cancer cells were engineered to have high levels of Siglec-15, the immune cells nearby changed their behavior. They stopped acting as defenders and instead transformed into a specific type known to help tumors grow. These transformed cells began producing a chemical messenger called CCL18, which is known to attract more immune cells to the area and encourage them to stay.
The study went deeper to find out exactly how the cancer cells were sending these instructions. The researchers analyzed the proteins secreted by the Siglec-15-rich cancer cells and found a specific molecule called DcR3. This molecule acts as a signal that triggers the immune cells to change. Further investigation revealed that the cancer cells produce DcR3 by activating a specific internal pathway, a chain of chemical reactions inside the cell that turns on the genes needed to make this protein. When the researchers blocked this pathway, the cancer cells stopped producing DcR3, and the immune cells no longer changed into their harmful form. This confirmed that the cancer cells rely on this specific internal switch to manipulate their surroundings.
The story does not end there, because the loop is completed by the immune cells' response. The researchers found that the harmful immune cells, now producing CCL18, send this chemical back to the cancer cells. There, it activates a different internal switch in the cancer cells, which tells them to make more Siglec-15. This means the cancer cells are not just the initiators; they are also the recipients of the signal. The more Siglec-15 the cancer cells have, the more they can convert immune cells, which in turn produce more CCL18, which tells the cancer cells to make even more Siglec-15. It is a continuous cycle of mutual reinforcement. The researchers tested this in mice, showing that when the cancer cells had high levels of Siglec-15, the tumors grew larger and faster. However, when they interrupted the cycle by blocking the production of DcR3 or the internal pathways involved, the tumors did not grow as aggressively.
This discovery provides a clear picture of how a specific protein can drive the progression of a difficult cancer. The researchers demonstrated that Siglec-15 is not just a marker of the disease but an active driver that creates a feedback loop between the tumor and the immune system. By understanding this specific chain of events, from the initial signal sent by the cancer cell to the return signal from the immune cell, scientists now have a more detailed map of the tumor's defenses. While this work does not offer an immediate cure, it highlights specific points in the cycle where future treatments could potentially intervene. If doctors can find a way to break this loop, perhaps by stopping the production of DcR3 or blocking the return signal, they might be able to prevent the tumor from recruiting its own army of helpers, leaving the cancer more vulnerable to the body's natural defenses or other therapies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.